SGLT2 inhibitors were associated with a 24% reduction in the odds of developing AF in a meta-analysis including 13 placebo-controlled trials [90], although this effect did not seem to translate into a significant reduction in stroke rates [91]. The gene discussed is SLC5A2; the disease is atrial fibrillation.